Actualizado 08/07/2015 02:24 CET

COMUNICADO: El biosimilar Retacrit(TM) demuestra ser efectivo en la anemia inducida por quimioterapia (y 2)

(1 )Michallet M, Luporsi E, Soubeyran P, et al. BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study. BMC Cancer 2014; 14:503 (July 10, 2014); http://www.biomedcentral.com/1471-2407/14/503/abstract [http://www.biomedcentral.com/1471-2407/14/503/abstract]. (2) Haustein R, Millas C, Höer A, et al. Saving money in the European healthcare systems with biosimilars. Generics and Biosimilars Initiative Journal. 2012;1(3-4):120-6. (3) Soubeyran P, Kurtz JE, Michallet M, et al. Biosimilar epoetin for the management of chemotherapy-induced anaemia in elderly patients: a subanalysis of the ORHEO study. Presented at the MASCC 2014 Symposium, 26-28 June 2014. Abstract disponible en http://mascc2014.meetingxpert.net/mascc_595/poster_97015/pro... [http://mascc2014.meetingxpert.net/mascc_595/poster_97015/pro...] [last accessed 23rd July 2014].

CONTACTO: CONTACTO: Medios europeos: James Osborn / Tarnia Ross, +44 207627 0990 o Comunidad financiera: Karen King / Ruth Venning, +1224-212-2711

Sitio Web: http://www.hospira.com/

Europa Press Comunicados Empresas